Boehringer Ingelheim FENS Award for exceptional research in neuroscience

Boehringer IngelheimThe 2008 Boehringer Ingelheim FENS Research Award goes to Pascal Fries, MD, PhD, from the F.C. Donders Centre for Cognitive Neuroimaging in Nijmegen, The Netherlands. At the Congress of the Federation of European Neuroscience Societies (FENS) taking place from 12-16 July 2008 in Geneva, on the occasion of a special lecture by the prize winner, the Boehringer Ingelheim FENS Research Award will be presented for the fourth time. Boehringer Ingelheim donates the award endowed with 25,000 Euro to young European scientists for exceptional research in any field of the neurosciences with the intention to ultimately promote potential benefits for patients by creating value through innovation.

36 year-old Pascal Fries received the award for his pioneering scientific work on the neurobiological organisation of human perception, how perception is influenced by attention, and which neural mechanisms instantiate these functions. His theories address one of the major challenges in latest cognitive neuroscience: to link descriptions and explanations of perception, action and memory at the psychological level to descriptions and explanations at the neuronal substrate level.

"It is a great honour for me to receive this award. I deeply appreciate the recognition of our scientific progress", said Dr Fries, who has conducted research at Institutes in Frankfurt, Germany, Maryland, USA and Nijmegen, the Netherlands.

"I hope that the results of our research help to better understand how behaviour and its neuronal basis is linked”, he added.

"Fostering science and research excellence is an important value and a key element of our strategy. We therefore continue to offer the Boehringer Ingelheim FENS Research Award - now for the fourth time - and therewith support the advancement of excellent young scientists", said Dr Manfred Haehl, Corporate Senior Vice President Medicine Boehringer Ingelheim.

"We again demonstrate Boehringer Ingelheim’s commitment to basic research in the area of neuroscience and are glad to be able to support the discovery and explanations of basic neuroscientific principles, independent of our pharmaceutical drug discovery”, said Dr Bernd Sommer, Head of Boehringer Ingelheim's Department of CNS Diseases Research, who presented the prize to Dr Fries.

The speech to honour Dr Fries was delivered by PD Dr Pico Caroni from the Friedrich-Miescher-Institute in Basel and member of the local organizing committee.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...